Utility of Genomic Sequencing Classifier in Managing Cytologically Indeterminate Oncocytic Thyroid Nodules.

Key Points

• This research aims to evaluate the effectiveness of the Afirma GSC for oncocytic thyroid nodules, focusing on its performance across Bethesda classifications.
• Evaluated genomic sequencing classifier performance
• Compared results from different Bethesda classifications
• Assessed the impact of Hashimoto's thyroiditis on test outcomes
• Afirma GSC demonstrates a high benign call rate for oncocytic nodules
• Performance improved over earlier molecular tests for Bethesda IV nodules
• Positive predictive value remains low for Bethesda III nodules with Hashimoto's thyroiditis